These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30717807)

  • 1. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer.
    Matsuyama T; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kawano T; Uetake H; Goel A
    Mol Cancer; 2019 Feb; 18(1):19. PubMed ID: 30717807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ITGBL1 promotes migration, invasion and predicts a poor prognosis in colorectal cancer.
    Qiu X; Feng JR; Qiu J; Liu L; Xie Y; Zhang YP; Liu J; Zhao Q
    Biomed Pharmacother; 2018 Aug; 104():172-180. PubMed ID: 29772438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
    Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
    Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 7. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer.
    Miyoshi J; Toden S; Yoshida K; Toiyama Y; Alberts SR; Kusunoki M; Sinicrope FA; Goel A
    Sci Rep; 2017 Mar; 7():43393. PubMed ID: 28262692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Individualized EMT-Related Gene Signature to Predict Recurrence-Free Survival in Stage II/III Colorectal Cancer Patients.
    Zhang W; Zhang X; Zhao D; Hu M; Ge X; Xia L
    Dig Dis Sci; 2022 Nov; 67(11):5116-5126. PubMed ID: 35094253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive analysis of potential gastric cancer prognostic biomarker ITGBL1 associated with immune infiltration and epithelial-mesenchymal transition.
    Wang Z; Fu L; Zhang J; Ge Y; Guo C; Wang R; Deng M; Wang Q; Wang Z
    Biomed Eng Online; 2022 May; 21(1):30. PubMed ID: 35596183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
    Schell MJ; Yang M; Missiaglia E; Delorenzi M; Soneson C; Yue B; Nebozhyn MV; Loboda A; Bloom G; Yeatman TJ
    Clin Cancer Res; 2016 Feb; 22(3):734-45. PubMed ID: 26446941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis identifies an immune-based prognostic signature for the mesenchymal identity in colorectal cancer.
    Zhang B; Wang L; Liu Z; Shao B; Jiang W; Shu P
    Medicine (Baltimore); 2020 Jun; 99(25):e20617. PubMed ID: 32569190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IBSP, a potential recurrence biomarker, promotes the progression of colorectal cancer via Fyn/β-catenin signaling pathway.
    Chen Y; Qin Y; Dai M; Liu L; Ni Y; Sun Q; Li L; Zhou Y; Qiu C; Jiang Y
    Cancer Med; 2021 Jun; 10(12):4030-4045. PubMed ID: 33987980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
    Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
    Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A molecular signature for the prediction of recurrence in colorectal cancer.
    Wang L; Shen X; Wang Z; Xiao X; Wei P; Wang Q; Ren F; Wang Y; Liu Z; Sheng W; Huang W; Zhou X; Du X
    Mol Cancer; 2015 Feb; 14(1):22. PubMed ID: 25645394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
    Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
    Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification.
    Sreekumar R; Harris S; Moutasim K; DeMateos R; Patel A; Emo K; White S; Yagci T; Tulchinsky E; Thomas G; Primrose JN; Sayan AE; Mirnezami AH
    JAMA Netw Open; 2018 Oct; 1(6):e183115. PubMed ID: 30646224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer.
    Kim SK; Kim SY; Kim CW; Roh SA; Ha YJ; Lee JL; Heo H; Cho DH; Lee JS; Kim YS; Kim JC
    Exp Mol Med; 2019 Oct; 51(10):1-12. PubMed ID: 31578316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a lipogenic genes panel for diagnosis and recurrence of colorectal cancer.
    Gharib E; Nasrinasrabadi P; Zali MR
    PLoS One; 2020; 15(3):e0229864. PubMed ID: 32155177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.
    Toiyama Y; Hur K; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
    Ann Surg; 2014 Apr; 259(4):735-43. PubMed ID: 23982750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ITGBL1 promotes cell migration and invasion through stimulating the TGF-β signalling pathway in hepatocellular carcinoma.
    Huang W; Yu D; Wang M; Han Y; Lin J; Wei D; Cai J; Li B; Chen P; Zhang X
    Cell Prolif; 2020 Jul; 53(7):e12836. PubMed ID: 32537856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.